Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KLK7 | P49862 | 1/20 | 0.38 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.37 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.37 |
| ▸ | STS | P08842 | 1/20 | 0.36 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6052900 | 1.00 | KLK7 (0.38) | KLK7GPR119KDM4EPKMNR1H2 | |
| SCHEMBL27043967 | 1.00 | KLK7 (0.38) | KLK7GPR119KDM4EPKMNR1H2 | |
| SCHEMBL30064881 | 1.00 | KLK7 (0.38) | KLK7GPR119KDM4EPKMNR1H2 | |
| SCHEMBL6052905 | 1.00 | KLK7 (0.38) | KLK7GPR119KDM4EPKMNR1H2 | |
| SCHEMBL30743002 | 0.94 | KLK7 (0.43) | KLK7GPR119USP30MEN1KMT2A | |
| SCHEMBL22555052 | 0.90 | GPR119 (0.40) | KLK7GPR119KDM4EPKMSTS | |
| SCHEMBL29889644 | 0.90 | GPR119 (0.40) | KLK7GPR119KDM4EPKMSTS | |
| SCHEMBL29889647 | 0.89 | GPR119 (0.40) | KLK7GPR119KDM4EPKMSTS | |
| SCHEMBL29889630 | 0.89 | KMT2A (0.36) | KMT2AALDH1A1NPC1 | |
| SCHEMBL30070935 | 0.87 | USP30 (0.37) | GPR119KDM4EPKMUSP30MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12630566-B2 | KRas G12D inhibitors | Mirati Therapeutics, Inc. (US) | 2026-05-19 | — | — | US | disclosed |
| US-20240309020-A1 | KRAS G12D INHIBITORS | ARRAY BIOPHARMA INC. | 2024-09-19 | — | — | US | disclosed |
| US-11964989-B2 | KRas G12D inhibitors | Mirati Therapeutics, Inc. (US) | 2024-04-23 | — | — | US | disclosed |
| US-20230077225-A1 | KRAS G12D INHIBITORS | Mirati Therapeutics, Inc. | 2023-03-09 | — | — | US | disclosed |
| US-11453683-B1 | KRas G12D inhibitors | Mirati Therapeutics, Inc. (US) | 2022-09-27 | — | — | US | disclosed |
| US-7625923-B2 | Bicyclic modulators of androgen receptor function | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-12-01 | — | — | US | disclosed |
| US-7625923-B2 | Bicyclic modulators of androgen receptor function | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-12-01 | — | — | US | disclosed |
| US-20050197359-A1 | Bicyclic modulators of androgen receptor function | BRISTOL-MYERS SQUIBB COMPANY | 2005-09-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050197359-A1 | Bicyclic modulators of androgen receptor function | AR, ESRRA, NR5A1 | KLK7 2190/4885GPR119 17/4885KDM4E 1219/4885 |
| US-20230077225-A1 | KRAS G12D INHIBITORS | KRAS, NRAS, HRAS | KLK7 2993/4885GPR119 1733/4885KDM4E 3340/4885 |
| US-12630566-B2 | KRas G12D inhibitors | KRAS, NRAS, HRAS | KLK7 4073/4885GPR119 1723/4885KDM4E 2825/4885 |
| US-11964989-B2 | KRas G12D inhibitors | KRAS, NRAS, HRAS | KLK7 2645/4885GPR119 1604/4885KDM4E 3843/4885 |
| US-11453683-B1 | KRas G12D inhibitors | KRAS, NRAS, HRAS | KLK7 2615/4885GPR119 1652/4885KDM4E 3868/4885 |
| US-20240309020-A1 | KRAS G12D INHIBITORS | KRAS, NRAS, HRAS | KLK7 2993/4885GPR119 1733/4885KDM4E 3340/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.